New antibody therapy aims to control rare amyloid disease
NCT ID NCT07151690
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase 2 trial tests a drug called CM336 in 21 people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. CM336 is a bispecific antibody that helps the immune system target and destroy the harmful cells making those proteins. The study will check if the drug can reduce protein levels and improve organ health, while monitoring for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LIGHT CHAIN AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CM336 (a bispecific antibody that helps immune cells attack harmful plasma cells)
What this could lead to
If successful, this could offer a new treatment option for people newly diagnosed with AL amyloidosis, potentially controlling the disease and improving organ function.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. Side effects like cytokine release syndrome are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.